DavidMischoulonMDPHD

Psychopharmacology, Psychosomatic Medicine

Professor of Psychiatry Harvard Medical School; Director of Depression Clinical and Research Program, MGH

Dr. Mischoulon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
15 Parkman St
Massachusetts General Hospital Wac812
Boston, MA 02114
Phone+1 617-724-5198

Fax+1 617-724-3028

Dr. David Mischoulon is a psychiatrist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Boston University School of Medicine and has been in practice 23 years. He also speaks multiple languages, including Spanish and French. He specializes in psychopharmacology and is experienced in clinical research, integrative medicine, depressive disorders, health outcomes research, and acupuncture therapy.

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1995 - 1998
Steward Carney HospitalInternship, Internal Medicine, 1994 - 1995
Boston University School of MedicineClass of 1994

PubMed

265 citations
Diet and depression: exploring the biological mechanisms of action
Wolfgang Marx, Melissa Lane, Meghan Hockey, Hajara Aslam, Michael Berk
Molecular Psychiatry. 2021-01-01
12 citations
Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19-34: A nationwide population study in South Korea.
Hyewon Kim, Yuwon Kim, Ji Hyun Baek, Maurizio Fava, David Mischoulon
Journal of Affective Disorders. 2020-03-15
104 citations
Frontal EEG predictors of treatment outcome in major depressive disorder.
Dan V. Iosifescu, Scott D. Greenwald, Philip H. Devlin, David Mischoulon, John W. Denninger
European Neuropsychopharmacology. 2009-11-01

Journal Articles

Association of Race and Ethnicity with Late-Life Depression Severity, Symptom Burden, and Care
David Mischoulon, Olivia I Okereke, JAMA Network Open
Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research
Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
Adjunctive S-adenosylmethionine (SAMe) in Treating Non-Remittent Major Depressive Disorder: An 8-Week Double-Blind, Randomized, Controlled Trial,
David Mischoulon, MD, European Neuropsychopharmacology

Association of Race and Ethnicity with Late-Life Depression Severity, Symptom Burden, and CareMarch 2020

Electroacupuncture Points to Improvements in Depression-Related InsomniaJuly 7th, 2022
Omega-3 Fish Oil Supplements Don’t Help Prevent Depression, Clinical Trial Finds – Massachusetts General HospitalDecember 21st, 2021
Psychological Resilience RequiredJune 24th, 2021
Join now to see all

Omega-3 Fatty Acids For Treatment Of Major DepressionNational Institute Of Mental Health2006–2010
Effect Of Protein Or Carbohydrate Intake On Mood And Appetite Symptoms OfNational Center For Research Resources2006–2007
Effect Of Protein Or Carbohydrate Intake On Mood And Appetite Symptoms Of MildNational Center For Research Resources2005–2006
Omega-3 Fatty Acids In The Treatment Of DepressionNational Center For Complementary &Alternative Medicine2001–2005